Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | 1 | — | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
Small cell lung carcinoma | D055752 | — | — | 1 | — | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Raltitrexed |
INN | raltitrexed |
Description | Raltitrexed (Thaltitrexed, Tomudex, TDX, ZD 1694) is an antimetabolite drug used in cancer chemotherapy. It is an inhibitor of thymidylate synthase, and is manufactured by AstraZeneca.
|
Classification | Small molecule |
Drug class | antineoplastic thymidylate synthetase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1 |
PDB | — |
CAS-ID | 112887-68-0 |
RxCUI | — |
ChEMBL ID | CHEMBL225071 |
ChEBI ID | 5847 |
PubChem CID | 104758 |
DrugBank | DB00293 |
UNII ID | FCB9EGG971 (ChemIDplus, GSRS) |